

Chanida Vinayanuwattikun

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8915269/chanida-vinayanuwattikun-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

106
citations

5
h-index

9
g-index

29
ext. papers

156
ext. citations

4.2
avg, IF

2.48
L-index

#	Paper	IF	Citations
24	Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.. <i>Scientific Reports</i> , 2022 , 12, 2167	4.9	1
23	GRP78/BiP determines senescence evasion cell fate after cisplatin-based chemotherapy. <i>Scientific Reports</i> , 2021 , 11, 22448	4.9	0
22	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021 , 11, 572740	5.3	2
21	Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization. <i>Cell Death Discovery</i> , 2021 , 7, 67	6.9	5
20	Artocarpin Targets Focal Adhesion Kinase-Dependent Epithelial to Mesenchymal Transition and Suppresses Migratory-Associated Integrins in Lung Cancer Cells. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
19	Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells. <i>Phytomedicine</i> , 2021 , 85, 153534	6.5	0
18	The equivalency study of novel current standard 3-drugs combination regimen (ondansetron, dexamethasone and olanzapine) to netupitant containing regimen for preventing high dose cisplatin induce nausea and vomiting treatment, double blind placebo control trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12100-12100	2.2	
17	Whole-exome sequencing in advanced-stage sensitizing EGFR mutation non-small cell lung cancer: Explore resistance biomarkers to EGFR TKI treatment.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9039-9039 ^{2.2}		
16	Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application. <i>Drug Delivery</i> , 2021 , 28, 1443-1454	7	1
15	Vimentin expression status is a potential biomarker for brain metastasis development in -mutant NSCLC patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 790-801	4.4	2
14	Caffeine Induces G0/G1 Cell Cycle Arrest and Inhibits Migration through Integrin α , β , and FAK/Akt/c-Myc Signaling Pathway.. <i>Molecules</i> , 2021 , 26,	4.8	1
13	Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1117-1125	3.6	
12	A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma. <i>British Journal of Cancer</i> , 2020 , 123, 1289-1301	8.7	7
11	Structure-Activity Relationships and Molecular Docking Analysis of Mcl-1 Targeting Renieramycin T Analogues in Patient-derived Lung Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	4
10	Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience. <i>BMC Cancer</i> , 2019 , 19, 1050	4.8	17
9	Feasibility Technique of Low-passage Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome. <i>Anticancer Research</i> , 2019 , 39, 6981-6988	2.3	5
8	A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 467-467	2.2	

7	Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10019-10019	2.2	
6	Comparing programmed death ligand-1 expression on tumor cells before and after acquiring resistance to tyrosine kinase inhibitor in EGFR harbouring non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11617-11617	2.2	
5	SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis). <i>Journal of Neuro-Oncology</i> , 2016 , 129, 395-403	4.8	3
4	The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence. <i>International Journal of Clinical Oncology</i> , 2014 , 19, 586-92	4.2	9
3	Prevalence of KRAS gene mutation in ampullary cancer in Thai patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15175-e15175	2.2	1
2	The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 67-76	4.9	19
1	Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1818-25	8.9	24